Warning: The NCBI web site requires JavaScript to function. more...
Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study.
Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, Hamann D.
Arthritis Res Ther. 2008;10(1):R12. Epub 2008 Jan 28.
Related citations
The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X, Jia R, Zhao J, Li Z.
J Rheumatol. 2009 Jun;36(6):1136-42. Epub 2009 May 15.
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1.
Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR.
Arthritis Rheum. 2007 Aug;56(8):2503-11.
Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, Sengül A.
Protein Pept Lett. 2008;15(3):314-7.
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieudé P, Meyer O, Chollet Martin S.
Arthritis Res Ther. 2008;10(6):R142. Epub 2008 Dec 10.
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, Uhlig T, Gaarder PI, Kvien TK.
Ann Rheum Dis. 2010 Feb;69(2):345-51. Epub 2009 Jul 30.
Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.
Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N.
Clin Chem Lab Med. 2009;47(12):1525-30.
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M.
Arthritis Res Ther. 2006;8(4):R119.
Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis.
Wagner E, Skoumal M, Bayer PM, Klaushofer K.
Rheumatol Int. 2009 Sep;29(11):1315-21. Epub 2009 Jan 28.
A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
Svärd A, Kastbom A, Söderlin MK, Reckner-Olsson Å, Skogh T.
J Rheumatol. 2011 Jul;38(7):1265-72. Epub 2011 Apr 1.
Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
J Rheumatol. 2007 Aug;34(8):1658-63. Epub 2007 Jul 1.
Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.
Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Fredj HB, Sammoud S, Ghedira I.
Rheumatol Int. 2008 Nov;29(1):59-62. Epub 2008 May 22.
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis.
Tesija-Kuna A, Grazio S, Miler M, Vukasovic I, Peric P, Vrkic N.
Clin Rheumatol. 2010 May;29(5):487-93. Epub 2010 Jan 13.
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
Arthritis Rheum. 2009 Aug;60(8):2232-41.
Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis.
Poulsom H, Charles PJ.
Clin Rev Allergy Immunol. 2008 Feb;34(1):4-10.
Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project.
Svärd A, Kastbom A, Reckner-Olsson A, Skogh T.
Arthritis Res Ther. 2008;10(4):R75. Epub 2008 Jul 4.
Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review.
Luime JJ, Colin EM, Hazes JM, Lubberts E.
Ann Rheum Dis. 2010 Feb;69(2):337-44. Epub 2009 Mar 15. Review.
Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.
Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y.
Clin Rheumatol. 2007 Oct;26(10):1627-33. Epub 2007 Feb 8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on